Boston Scientific Corporation $BSX Shares Sold by TD Waterhouse Canada Inc.

Key Points

• TD Waterhouse Canada cut its Boston Scientific position by 41% in the second quarter, selling 122,142 shares and retaining 176,096 shares valued at approximately $7.6 million. Institutional investors and hedge funds collectively own 89.07% of the company.
• Company insiders increased their holdings: CEO Michael F. Mahoney bought 186,240 shares for about $9.0 million, while Director Edward J. Ludwig purchased 5,000 shares. Insiders acquired roughly $9.4 million of stock over the past 90 days.
• Analysts maintain a generally positive view, with a consensus rating of “Moderate Buy” and an average price target of $71.62. Boston Scientific recently beat quarterly earnings and revenue estimates, and its board authorized a $5 billion share-repurchase program covering up to 6.4% of outstanding shares.

TD Waterhouse Canada Inc. decreased its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 41.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 176,096 shares of the medical equipment provider's stock after selling 122,142 shares during the period. TD Waterhouse Canada Inc.'s holdings in Boston Scientific were worth $7,584,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Syntax Research Inc. bought a new position in Boston Scientific in the 2nd quarter worth approximately $113,000. Concurrent Investment Advisors LLC raised its stake in Boston Scientific by 77.0% during the 2nd quarter. Concurrent Investment Advisors LLC now owns 55,565 shares of the medical equipment provider's stock valued at $2,371,000 after acquiring an additional 24,166 shares in the last quarter. NEOS Investment Management LLC boosted its position in Boston Scientific by 10.6% during the 2nd quarter. NEOS Investment Management LLC now owns 243,837 shares of the medical equipment provider's stock worth $10,407,000 after acquiring an additional 23,291 shares during the period. Allen Mooney & Barnes Investment Advisors LLC acquired a new position in Boston Scientific during the 2nd quarter worth $318,000. Finally, AXQ Capital LP grew its stake in shares of Boston Scientific by 21.5% in the second quarter. AXQ Capital LP now owns 121,522 shares of the medical equipment provider's stock worth $5,187,000 after purchasing an additional 21,466 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Insider Buying and Selling

In other Boston Scientific news, Director Edward J. Ludwig purchased 5,000 shares of the firm's stock in a transaction on Friday, July 31st. The shares were purchased at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the transaction, the director owned 30,359 shares in the company, valued at $1,380,727.32. This represents a 19.72% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael F. Mahoney purchased 186,240 shares of the company's stock in a transaction on Monday, August 3rd. The stock was bought at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the acquisition, the chief executive officer directly owned 1,590,024 shares of the company's stock, valued at $76,845,859.92. This represents a 13.27% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 194,522 shares of company stock worth $9,385,210 in the last ninety days. 0.34% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Evercore set a $65.00 price objective on shares of Boston Scientific in a research note on Monday, July 6th. Needham & Company LLC lowered their target price on shares of Boston Scientific from $77.00 to $57.00 and set a "buy" rating on the stock in a research note on Wednesday, July 8th. Citigroup dropped their price target on shares of Boston Scientific from $70.00 to $61.00 and set a "buy" rating on the stock in a research report on Thursday, July 30th. Oppenheimer reduced their price target on shares of Boston Scientific from $90.00 to $85.00 and set an "outperform" rating for the company in a research note on Monday, July 27th. Finally, Zacks Research cut shares of Boston Scientific from a "hold" rating to a "strong sell" rating in a report on Friday, June 5th. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $71.62.

Boston Scientific Trading Up 1.9%

Shares of BSX stock opened at $47.85 on Friday. The stock has a 50-day simple moving average of $46.90 and a 200 day simple moving average of $55.74. The stock has a market capitalization of $69.35 billion, a P/E ratio of 19.37, a P/E/G ratio of 1.10 and a beta of 0.57. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $109.50. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion for the quarter, compared to analysts' expectations of $5.38 billion. During the same period in the previous year, the business earned $0.75 earnings per share. Boston Scientific's revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, sell-side analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has initiated a share repurchase program on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback programs are typically a sign that the company's leadership believes its shares are undervalued.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Shipping operations are being restored after a cyberattack. Boston Scientific has begun resuming product shipments, suggesting the disruption may be contained and reducing concerns about a prolonged impact on revenue and customer relationships. Boston Scientific begins to restore shipping after cyberattack
• Positive Sentiment: Interventional cardiology and vascular therapy growth remains a key support. ICVT sales reportedly increased 15%, helped by demand for coronary therapies, new devices and strategic deals. Sustained momentum in this business could help offset pressure elsewhere. Boston Scientific's ICVT Business Gains Momentum
• Positive Sentiment: Clinical progress may expand the heart-failure opportunity. The completion of the LUX-Dx TRENDS study provides additional data on Boston Scientific’s implantable monitoring technology, although the commercial impact depends on study results and adoption. Boston Scientific’s LUX-Dx TRENDS Study
• Neutral Sentiment: Heavy call-option activity indicates some traders are positioning for a rebound, but options flows do not guarantee future stock performance. Stock Traders Buy High Volume of Call Options on Boston Scientific
• Negative Sentiment: Product recalls remain a significant overhang. Boston Scientific recalled Infinion CX spinal-cord-stimulator leads because of fracture risk following 1,081 injury reports, while additional worldwide recalls could increase costs, regulatory scrutiny and liability exposure. Boston Scientific Recalls Spinal Cord Stimulator Leads
• Negative Sentiment: The cyberattack disrupted shipments, and concerns about weaker 2026 guidance and broader business pressure have weighed on the outlook. The recent decline before the latest recovery reflects investor caution despite Boston Scientific’s prior earnings and revenue beats. Cyberattack and Weak 2026 Outlook Weigh on BSX

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source